Albion News

Exco InTouch
Albion has led a £3.2m investment round in Exco InTouch (“Exco”), a leading electronic Patient Reported Outcomes (“ePRO”) and patient engagement software business. Founder investor, Scottish Equity Partners (“SEP”), also participated in the round and remains the company’s largest shareholder. Founded in 2004 by its current CEO, Tim Davis, Exco provides mobile and digital services to pharmaceutical companies for the engagement and collection of information from patients in clinical trials and real-life settings (ePRO). This rapidly growing sector is being driven by the increasing need to... read more
Exco InTouch today announces that one million patients have now benefited from the company’s firmly established and industry leading platform. This significant number underlines the company’s established leadership position in the market and highlights the broad reach of Exco InTouch’s services. The company’s platform is highly scalable with the proven capability to support cross-border programs with large patient populations. As a consequence, at any one time hundreds of thousands of patients across multiple territories, time zones and languages benefit from Exco InTouch’s software and... read more
Masters Speciality Pharma has announced the strengthening of its capabilities in Brazil through its acquisition of Masters Distribution Brazil. The new company, located in São Caetano do Sul, São Paulo, will become part of the Master Speciality Pharma Group, and contribute to the group’s future expansion and growth plans in Latin America. Since its incorporation eight years ago, Masters Pharmaceuticals Ltda, Brazil – the regional subsidiary of the Masters Speciality Pharma group – has focused on early-access programs through the named patient supply (NPS) of unlicensed medicines to patients... read more
– Study shows that ROCA® detects 86% of women with ovarian cancer before there are any symptoms; twice as many than the use of a single assessment of CA125.  – When ROCA® is used with an ultrasound scan as the follow up test, screening can rule out almost 100% of women who are cancer-free.  – Based on these impressive data, Abcodia prepares to launch ROCA® into the private market in 2015.  Abcodia, a specialist company engaged in the development of tests for the early detection of cancer, is to make ROCA® available as an innovative ovarian cancer screening test this year, on the back of new... read more
Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) - 22 October 2014  Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden.  Masters has 30 years experience in the ethical and compliant supply of drugs to... read more
Chris Roche will succeed David Sibbald in the role of chief executive, David will become executive chairman. Roche joined Aridhia a year ago as chief commercial officer and is credited with bringing a more commercial focus to the business as it shifts from traditional licensing of software to a central cloud-based delivery model. The firm recently announced it was partnering fellow Scottish health technology pioneer Craneware to target the US market.   Roche, who prior to joining Aridhia worked for global IT company EMC for 14 years, said: “My focus is now to accelerate our own business model... read more
Silent Herdsman announces the launch of mySilent Herdsman Health Alert. The mySilent Herdsman Health Alert software-service has been developed to provide early identification of animal illness before being observed or identified as so by a farmer, staff member or vet, and builds on research carried out during a three year programme supported by Innovate UK1. It has been proven to accurately and reliably alert farms to the signs of illness, most commonly to the early onset of acidosis, ketosis, mastitis/E coli mastitis and lameness. The 24 x 7 software-service continually monitors eating and... read more
Albion announces that it is increasing its exposure to the independent education sector by investing up to £9.5 million in Radnor House School (“RHS”) to fund the acquisition of Combe Bank School (“Combe Bank”), a co-educational independent school for students aged three to 18, located near Sevenoaks, Kent.  In 2010 Albion invested £8.7 million in Radnor House School, a new co-educational independent day school for students aged 7- 18 in Twickenham, South West London. Since then the school has performed exceptionally well and has established an excellent reputation. Since opening its pupil... read more
Albion announces that it is increasing its exposure to the independent education sector by investing up to £9.5 million in Radnor House School (“RHS”) to fund the acquisition of Combe Bank School (“Combe Bank”), a co-educational independent school for students aged three to 18, located near Sevenoaks, Kent.   In 2010 Albion invested £8.7 million in Radnor House School, a new co-educational independent day school for students aged 7- 18 in Twickenham, South West London.   Since then the school has performed exceptionally well and has established an excellent reputation. Since opening its pupil... read more
Albion announces that it is increasing its exposure to the independent education sector by investing up to £9.5 million in Radnor House School (“RHS”) to fund the acquisition of Combe Bank School (“Combe Bank”), a co-educational independent school for students aged three to 18, located near Sevenoaks, Kent. In 2010 Albion invested £8.7 million in Radnor House School, a new co-educational independent day school for students aged 7- 18 in Twickenham, South West London. Since then the school has performed exceptionally well and has established an excellent reputation. Since opening its pupil... read more

Pages